ES2211373T1 - Nuevas formas cristalinas de oxcarbazepina y procedimientos para su preparacion. - Google Patents
Nuevas formas cristalinas de oxcarbazepina y procedimientos para su preparacion.Info
- Publication number
- ES2211373T1 ES2211373T1 ES02718948T ES02718948T ES2211373T1 ES 2211373 T1 ES2211373 T1 ES 2211373T1 ES 02718948 T ES02718948 T ES 02718948T ES 02718948 T ES02718948 T ES 02718948T ES 2211373 T1 ES2211373 T1 ES 2211373T1
- Authority
- ES
- Spain
- Prior art keywords
- oxcarbazepine
- solution
- approximately
- procedure
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 title claims abstract 77
- 238000000034 method Methods 0.000 title claims abstract 48
- 238000002360 preparation method Methods 0.000 title claims abstract 9
- 229960001816 oxcarbazepine Drugs 0.000 claims abstract 69
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims abstract 30
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract 18
- 239000000203 mixture Substances 0.000 claims abstract 4
- 239000000843 powder Substances 0.000 claims abstract 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 20
- 239000002552 dosage form Substances 0.000 claims 11
- 239000012453 solvate Substances 0.000 claims 10
- 239000002244 precipitate Substances 0.000 claims 8
- 230000015572 biosynthetic process Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 238000001816 cooling Methods 0.000 claims 4
- 238000002441 X-ray diffraction Methods 0.000 claims 3
- 238000001704 evaporation Methods 0.000 claims 3
- 230000008020 evaporation Effects 0.000 claims 3
- 239000003586 protic polar solvent Substances 0.000 claims 3
- 238000010992 reflux Methods 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 230000000903 blocking effect Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 229940100692 oral suspension Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 102000008538 voltage-gated sodium channel activity proteins Human genes 0.000 claims 1
- 108040002416 voltage-gated sodium channel activity proteins Proteins 0.000 claims 1
- 239000002699 waste material Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26831401P | 2001-02-12 | 2001-02-12 | |
| US268314P | 2001-02-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2211373T1 true ES2211373T1 (es) | 2004-07-16 |
Family
ID=23022405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES02718948T Pending ES2211373T1 (es) | 2001-02-12 | 2002-02-12 | Nuevas formas cristalinas de oxcarbazepina y procedimientos para su preparacion. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7183272B2 (https=) |
| EP (1) | EP1368322A4 (https=) |
| JP (1) | JP2004526706A (https=) |
| AU (1) | AU2002250057A1 (https=) |
| CA (1) | CA2437402A1 (https=) |
| DE (1) | DE02718948T1 (https=) |
| ES (1) | ES2211373T1 (https=) |
| HU (1) | HUP0303154A3 (https=) |
| IL (1) | IL157351A0 (https=) |
| TR (1) | TR200400313T3 (https=) |
| WO (1) | WO2002064557A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7091339B2 (en) | 2002-06-14 | 2006-08-15 | Taro Pharmaceuticals Usa, Inc. | Method of preparing a 5H-dibenz(b,f)azepine-5-carboxamide |
| GB0223224D0 (en) * | 2002-10-07 | 2002-11-13 | Novartis Ag | Organic compounds |
| US20060166968A1 (en) * | 2004-07-16 | 2006-07-27 | Sundaram Venkataraman | Crystalline form of oxcarbazepine |
| US7563930B2 (en) * | 2005-11-22 | 2009-07-21 | Teva Pharmaceutical Industries Ltd | Crystal forms of Cinacalcet HCI and processes for their preparation |
| EP2662374A1 (en) * | 2006-04-05 | 2013-11-13 | OPKO Health, Inc. | Salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl]-8-phenyl-1,7 -diaza-spiro[4.5]decan-2-one and preparation process therefor |
| ES2360423T3 (es) | 2006-04-26 | 2011-06-03 | Supernus Pharmaceuticals, Inc. | Preparaciones de liberación controlada de oxcarbazepina que tienen perfil de liberación sigmoidal. |
| ITMI20062449A1 (it) * | 2006-12-19 | 2008-06-20 | Dipharma Spa | Forma cristallina di rabeprazolo sodico |
| ITMI20071502A1 (it) * | 2007-07-25 | 2009-01-26 | Archimica Srl | Procedimento per la preparazione di formulazioni solide a rilascio controllato contenenti oxcarbazepina e formulazioni ottenibili con tale procedimento |
| CN102573475B (zh) * | 2009-08-14 | 2016-01-20 | 欧科生医股份有限公司 | 神经激肽-1拮抗剂的静脉内制剂 |
| WO2011071853A2 (en) | 2009-12-07 | 2011-06-16 | Academic Pharmaceuticals Incorporated | Parenteral formulation of clopidogrel |
| AR099354A1 (es) | 2013-11-15 | 2016-07-20 | Akebia Therapeutics Inc | Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos |
| BR112021005955A2 (pt) | 2018-09-28 | 2021-07-27 | Griffith University | agentes e métodos para modular atividade de patógeno |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH500196A (de) * | 1969-03-10 | 1970-12-15 | Ciba Geigy Ag | Verfahren zur Herstellung von neuen Azepinderivaten |
| FI75561C (fi) * | 1979-10-30 | 1988-07-11 | Ciba Geigy Ag | Foerfarande foer framstaellning av 5- karbamoyl-10-oxo-10,11-dihydro-5h-dibens/b,f/azepin och daertill noedvaendiga mellanprodukter. |
| FR2700117B1 (fr) * | 1993-01-07 | 1995-02-03 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens. |
| IT1272897B (it) * | 1995-01-13 | 1997-07-01 | I F C Iniziative Finanziaarie | Processo per la produzione di 10-oxo-10,11-diidro-sh- -dibenz(b,f) azepin-5-carbossiammide |
| US6670472B2 (en) * | 2001-10-09 | 2003-12-30 | Max India Limited | Process for the preparation of 10-methoxycarbamazepine |
| US7091339B2 (en) | 2002-06-14 | 2006-08-15 | Taro Pharmaceuticals Usa, Inc. | Method of preparing a 5H-dibenz(b,f)azepine-5-carboxamide |
-
2002
- 2002-02-12 JP JP2002564490A patent/JP2004526706A/ja active Pending
- 2002-02-12 IL IL15735102A patent/IL157351A0/xx unknown
- 2002-02-12 WO PCT/US2002/004065 patent/WO2002064557A2/en not_active Ceased
- 2002-02-12 DE DE0001368322T patent/DE02718948T1/de active Pending
- 2002-02-12 AU AU2002250057A patent/AU2002250057A1/en not_active Abandoned
- 2002-02-12 EP EP02718948A patent/EP1368322A4/en not_active Withdrawn
- 2002-02-12 HU HU0303154A patent/HUP0303154A3/hu unknown
- 2002-02-12 ES ES02718948T patent/ES2211373T1/es active Pending
- 2002-02-12 US US10/074,181 patent/US7183272B2/en not_active Expired - Fee Related
- 2002-02-12 TR TR200400313T patent/TR200400313T3/xx unknown
- 2002-02-12 CA CA002437402A patent/CA2437402A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE02718948T1 (de) | 2004-07-08 |
| TR200400313T3 (tr) | 2004-04-21 |
| EP1368322A2 (en) | 2003-12-10 |
| HUP0303154A3 (en) | 2009-08-28 |
| WO2002064557A3 (en) | 2002-10-24 |
| US20030004154A1 (en) | 2003-01-02 |
| IL157351A0 (en) | 2004-02-19 |
| US7183272B2 (en) | 2007-02-27 |
| CA2437402A1 (en) | 2002-08-22 |
| WO2002064557A9 (en) | 2002-11-28 |
| AU2002250057A1 (en) | 2002-08-28 |
| WO2002064557A2 (en) | 2002-08-22 |
| JP2004526706A (ja) | 2004-09-02 |
| EP1368322A4 (en) | 2004-03-17 |
| HUP0303154A2 (hu) | 2004-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2211373T1 (es) | Nuevas formas cristalinas de oxcarbazepina y procedimientos para su preparacion. | |
| ES2877404T3 (es) | Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue | |
| ES2961843T3 (es) | Gamma-carbolinas condensadas con heterociclo deuteradas como antagonistas de los receptores de 5-HT2A | |
| KR101496508B1 (ko) | 독성을 감소시키고 질환을 치료하거나 예방하기 위한 화합물, 조성물과 방법 | |
| ES2893298T3 (es) | Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue | |
| ES2882488T3 (es) | Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue | |
| AR023346A1 (es) | Compuestos derivados biciclicos substituidos utiles como agentes contra el cancer, uso de los mismos para preparar un medicamento, composicionesfarmaceuticas y procedimiento de preparacion de los compuestos | |
| US20220211678A1 (en) | Uses of (+)-a-dihydrotetrabenazine in methods of treating movement disorder | |
| RO118372B1 (ro) | Antagonisti nepeptidici ai receptorului de tahikinina, procedeu de preparare a acestora si compozitie farmaceutica | |
| CA2944755A1 (en) | Organic compounds | |
| UY25993A1 (es) | Procedimiento para preparar derivados del acido hidroxi-pipecolato hidroxamico | |
| MX2019011491A (es) | Formulaciones de niraparib. | |
| SE0104341D0 (sv) | New use | |
| AR044775A1 (es) | Composiciones farmaceuticas de atorvastatina | |
| WO2005082368A1 (en) | Isoquinoline derivatives and methods of use thereof | |
| UY27592A1 (es) | Nuevo uso | |
| RU2010150478A (ru) | Способы профилактики и лечения нейродегенеративных заболеваний | |
| RU2000103033A (ru) | Термодинамически стабильная модификация 1-(4-карбазолилокси)-3-[2-(2-метоксифенокси)этиламино]-2-пропанола, способ ее получения и содержащие ее фармацевтические композиции | |
| JPH0144170B2 (https=) | ||
| AR050615A1 (es) | Composiciones farmaceuticas para la administracion oral | |
| ES3055898T3 (en) | Alpha-truxillic acid derivatives and pharmaceutical compositions thereof | |
| RU2022104034A (ru) | Фармацевтические композиции | |
| AR030039A1 (es) | Composicion farmaceutica que comprende una droga inhibidora selectiva de la ciclooxigenasa-2, su uso en la fabricacion de un medicamento para tratar o prevenir afecciones mediadas por la ciclooxigenasa-2 y metodo para hacer dicho medicamento | |
| JP2004526706A5 (https=) | ||
| AR044869A1 (es) | Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, su uso para fabricar un medicamento y procedimiento para su preparacion |